Geraldine Zamora-Abrahan

Geraldine Zamora-Abrahan

Auto-generated profile, based on publicly available information

Geraldine Zamora-Abrahan

Division of Rheumatology, Department of Medicine, University of the Philippines - Philippine General Hospital, University of the Philippines Manila, Manila, Philippines

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Rheumatology and Immunology Research
Verified
Journal Article
Open access
PDF file
GZGeraldine T. Zamora
Geraldine T. Zamora
Social media has unprecedentedly impacted the world, and this includes patients and physicians alike. This article provides a glimpse of the pros and cons of social media to both parties, and how, despite its pitfalls, rheumatologists can put its use in daily practice to help bridge the gap between, and among, rheumatologists and patients to ultimately improve patient outcomes.

13 March 2023 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
LTLisa S. Traboco
Lisa S. Traboco
GZGeraldine Zamora-Abrahan
Geraldine Zamora-Abrahan
SRSheila Marie Reyes
Sheila Marie Reyes
POPavel V. Ovseiko
Pavel V. Ovseiko
NSNimrat Kaur Sandhu
Nimrat Kaur Sandhu
LGLatika Gupta
Latika Gupta

2 March 2021 in The Open Rheumatology Journal
Verified
Journal Article
Open access
PDF file
ESEvelyn O. Salido
Evelyn O. Salido
CTCherica Tee
Cherica Tee
PRPatrick W. C. Reyes
Patrick W. C. Reyes
HRHeizel B. M. Reyes
Heizel B. M. Reyes
GZGeraldine T. Zamora
Geraldine T. Zamora
MTMichael L. Lucas Tee
Michael L. Lucas Tee
Background: During the first three months of the COVID-19 pandemic in the Philippines, there was a supply shortage of hydroxychloroquine and methotrexate. Limited access to medication and the life changes resulting from the COVID-19 pandemic may predispose patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) to disease flares. Objective: This study aimed to investigate self-reported symptoms of disease flares among patients with rheumatoid arthritis or systemic lupus erythematosus during the COVID-19 pandemic. Methods: A total of 512 completed online surveys from patients with SLE or RA were collected. The data included sociodemographic characteristics, self-reported physical symptoms, health service utilization, and availability of hydroxychloroquine and methotrexate. Results: Seventy-nine percent of respondents had lupus, while 21% had RA. One-third of the cohort had contact with their attending physician during the two-month quarantine period prior to the survey. Eighty-two percent were prescribed hydroxychloroquine and 23.4% were prescribed methotrexate; but 68.6% and 65%, respectively, had “irregular” intake of these medicines due to unavailability. The current health status was reported as good by 66.2%; 24% had no symptoms during the two-week period prior to the survey. The most common symptoms experienced were joint pain (51%), muscle pain (35%), headache (26.8%), and skin rash (19.1%). Five percent had a combination of these four most common symptoms. Irregular supply of hydroxychloroquine among patients with SLE (n=323) was associated with more frequent occurrence of muscle pain (40.6% vs 27.9%, p=0.03) or rash (27.4% vs 11.7%, p<0.001). Irregular supply of methotrexate among RA patients prescribed hydroxychloroquine and methotrexate (n=36) was associated with more frequent occurrence of joint pains with or without swelling (73.9% vs 38.5%, p=0.04). Irregular supply of hydroxychloroquine was associated with less frequent occurrence of dizziness (0 vs 66.7%, p<0.001) among RA patients (n=18). Conclusion: In our cohort of RA and SLE, the majority reported at least one symptom that may indicate disease flare. There was a significant association between the irregular supply of hydroxychloroquine or methotrexate with the presence of muscle pain, rash, or joint pains during the 14-day period prior to the survey.

1 August 2023 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MPMario Panaligan
Mario Panaligan
MRMinette Claire Rosario
Minette Claire Rosario
RZRicardo Zotomayor
Ricardo Zotomayor
GZGeraldine Zamora
Geraldine Zamora
GBGyneth Lourdes Bibera
Gyneth Lourdes Bibera
JJJoselito Javier
Joselito Javier
Although 1 in 3 people globally are expected to develop herpes zoster (HZ; i.e. shingles), HZ vaccination is not currently part of the Philippine National Immunization Program and HZ is not considered as one of the main vaccine-preventable diseases highlighted by the Department of Health. We report the findings from two advisory boards held with healthcare professionals (HCPs) to understand the current landscape of HZ management and prevention in the Philippines. The first advisory board focused on the management and prevention of HZ in patients aged ≥50 years, the second in immunocompromised patients aged ≥18 years. HCPs reported seeing HZ cases across specialties, with the most common complication being postherpetic neuralgia. HZ was reported to impose a substantial burden on patients, due to both the cost of treatment and distress caused due to pain. HZ could also complicate the treatment of ongoing conditions. HCPs agreed that the introduction of the recombinant zoster vaccine, which was recently approved by the Philippines Food and Drug Administration, could help in the prevention of HZ, addressing the needs of both HCPs and patients. Suggested steps to establish HZ vaccination in the Philippines included improved HCP and patient education, and establishing local HZ vaccine recommendations.

13 January 2023 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
GZGeraldine Tong Zamora-Abrahan
Geraldine Tong Zamora-Abrahan
ESEvelyn Osio Salido
Evelyn Osio Salido
JLJuan Javier Tayengco Lichauco
Juan Javier Tayengco Lichauco
AGAnna Kristina Manahan Gutierrez-Rubio
Anna Kristina Manahan Gutierrez-Rubio
IRIvy Catherine Talavera Rivera-Go
Ivy Catherine Talavera Rivera-Go
ARAdora Gatlabayan Del Rosario
Adora Gatlabayan Del Rosario
We described the profile and outcome of Filipino patients with inflammatory rheumatic diseases (IRDs) who developed COVID-19 (IRD-C19) during the onset of the pandemic, prior to vaccinations and variants. We obtained de-identified data of Filipino patients with IRD-C19 from the Global Rheumatology Alliance registry from March 2020 to August 2021. Descriptive statistics and multivariate analyses were applied. Registered were 164 patients (mean age 44 years; 70% female). The most common IRDs were systemic lupus erythematosus (SLE, 41.4%), rheumatoid arthritis (RA, 15.2%), and gout (14.6%). Majority were receiving conventional DMARDs (59.1%) and/or glucocorticoid therapy (GC, 51.2%). Half (58.5%) were hospitalized, with risk higher in active IRD (OR 3.7), heart disease (8.52), and hypertension (8.73); and lower in SLE patients (0.15). Among hospitalized patients, 76% needed supplemental oxygen. Heart disease (6.28), hypertension (7.6), and moderate-to-high IRD activity (3.37) were associated with higher odds of requiring oxygen supplementation. Hypertension was associated with mechanical ventilation (8.23). Twenty-four (15%) patients died, with odds lower if on prednisone ≥ 10 mg/day (0.17) and with other autoimmune IRDs aside from SLE and RA (0.05). Among patients with IRD-C19 prior to vaccinations and variants, higher disease activity, hypertension, and heart disease were associated with poorer outcomes. Prednisone ≥ 10 mg/day was associated with lower odds of death. This study provides valuable historical information, emphasizing the need for continued data collection to clarify COVID-19’s impact. Key Points • Filipinos with rheumatic diseases who developed COVID-19 at the pandemic outset had manifestations similar to other ethnicities and geographic locations. • Hospitalization and need for oxygen supplementation were higher among patients with active inflammatory rheumatic disease, heart disease, and hypertension. • Use of csDMARDs did not show negative effects on COVID-19 outcomes. • A reduced odds of dying was found among patients on prednisone > 10 mg/day.

4 September 2020 in Research Square
Verified
Preprint
Open access
PDF file
ESEvelyn O. Salido
Evelyn O. Salido
CTCherica Tee
Cherica Tee
PRPatrick Wincy C. Reyes
Patrick Wincy C. Reyes
BRBernadette Heizel M. Reyes
Bernadette Heizel M. Reyes
GZGeraldine T. Zamora
Geraldine T. Zamora
MTMichael L. Lucas Tee
Michael L. Lucas Tee
Background. During the first three months of the COVID-19 pandemic in the Philippines, there was a supply shortage of hydroxychloroquine and methotrexate. This problem with medication access and the life changes resulting from the COVID-19 pandemic may predispose patients with rheumatoid arthritis (RA) or lupus erythematosus (LE) to disease flares.Objective. This study aims to investigate self-reported symptoms of disease flares among patients with rheumatoid arthritis or lupus erythematosus during the COVID-19 pandemic.Methods. A total of 512 completed online surveys from patients with LE or RA were collected. The gathered data included sociodemographic characteristics, self-reported physical symptoms, health service utilization, and availability of hydroxychloroquine and methotrexate.Results. Seventy-nine percent of respondents had lupus, while 21% had RA. One-third of the cohort had contact with their attending physician during the two-month quarantine period prior to the survey. Eighty-two percent were on hydroxychloroquine and 23.4% were on methotrexate; but 68.6% and 65%, respectively, of those prescribed had irregular intake of these medicines due to unavailability. The current health status was reported as good by 66.2%; 24% had no symptoms during the two-week period prior to the survey. The most common symptoms experienced were joint pain (67.4%), muscle pain (46.3%), headache (35.4%), and skin rash (25.4%). Five percent had a combination of these four most common symptoms. There was a higher proportion of patients with irregular supply of hydroxychloroquine with joint pains (54.9% versus 41.7%, p=0.012) and rash (24.7% versus 9.8%, p<0.001, Table 3).Conclusion. In our cohort of RA or LE, the majority reported at least one symptom that may indicate disease flare. There were more patients with joint pains or rash among those with irregular supply of hydroxychloroquine.